Holen Sie sich die Stockscreener-App
1.99
0.00%
0.00
Handel nachbörslich:
1.96
-0.03
-1.51%
Schlusskurs vom Vortag:
$1.99
Offen:
$1.99
24-Stunden-Volumen:
528.32K
Relative Volume:
1.14
Marktkapitalisierung:
$209.67M
Einnahmen:
$17.91M
Nettoeinkommen (Verlust:
$-47.66M
KGV:
-4.3775
EPS:
-0.4546
Netto-Cashflow:
$-62.63M
1W Leistung:
+8.74%
1M Leistung:
+9.34%
6M Leistung:
-26.57%
1J Leistung:
+67.23%
1-Tages-Spanne:
$1.895
$2.0185
1-Wochen-Bereich:
$1.75
$2.15
52-Wochen-Spanne:
$1.10
$3.10
Proqr Therapeutics N V Stock (PRQR) Company Profile
Firmenname
Proqr Therapeutics N V
Sektor
Branche
Telefon
-
Adresse
-
Compare PRQR vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
1.99 | 209.67M | 17.91M | -47.66M | -62.63M | -0.4546 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-12 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-04-29 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-04-29 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-29 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-11-08 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2023-03-30 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-02-11 | Herabstufung | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | Herabstufung | Stifel | Buy → Hold |
| 2022-02-01 | Eingeleitet | Raymond James | Strong Buy |
| 2021-05-03 | Eingeleitet | Stifel | Buy |
| 2021-03-25 | Bestätigt | Citigroup | Buy |
| 2020-11-03 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-03-12 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-12-19 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-11-15 | Eingeleitet | Citigroup | Buy |
| 2018-09-19 | Eingeleitet | Evercore ISI | Outperform |
| 2017-09-26 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-06-20 | Eingeleitet | Chardan Capital Markets | Neutral |
| 2014-10-15 | Eingeleitet | Deutsche Bank | Buy |
| 2014-10-13 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Proqr Therapeutics N V Aktie (PRQR) Neueste Nachrichten
Jobs Data: Can ProQR Therapeutics NV withstand a market correctionQuarterly Investment Review & AI Based Buy and Sell Signals - baoquankhu1.vn
Stock Analysis: Can ProQR Therapeutics NV outperform under higher oil prices2026 Short Interest & Precise Trade Entry Recommendations - baoquankhu1.vn
Volume Report: Is ProQR Therapeutics NV currently under institutional pressure2026 Gainers & Expert Verified Movement Alerts - baoquankhu1.vn
Chardan Capital Maintains ProQR Therapeutics N.V. (PRQR) Buy Recommendation - MSN
If You Invested $1,000 in Proqr Therapeuti (PRQR) - Stock Titan
ProQR Therapeutics: Waiting On Proof As AX-0810 Data Approaches (NASDAQ:PRQR) - Seeking Alpha
PRQR: Chardan Capital Maintains Buy Rating with $4.00 Price Targ - GuruFocus
Proqr Therapeutics expands early-stage pipeline - BioWorld News
ProQR Therapeutics (NASDAQ:PRQR) Earns "Buy" Rating from Chardan Capital - MarketBeat
ProQR Therapeutics Unveils New RNA Editing Programs; AX-0810 Phase 1 Target Data Due This Quarter - Defense World
Aberdeen Group Boosts Stake in ProQR Therapeutics - National Today
Aberdeen Group plc Has $5.96 Million Holdings in ProQR Therapeutics N.V. $PRQR - MarketBeat
ProQR (PRQR) Partners with Ginkgo Bioworks to Boost AI-Driven Dr - GuruFocus
ProQR partners with Ginkgo on AI drug discovery platform By Investing.com - Investing.com Australia
ProQR Therapeutics Virtual Investor Event Transcript - GuruFocus
ProQR updates RNA editing pipeline, targets biliary atresia By Investing.com - Investing.com Australia
ProQR forms advisory board, partnership with Ginkgo as part of AI strategy - MSN
ProQR Forms AI Advisory Board and Partners with Ginkgo Bioworks - Intellectia AI
ProQR Details Axiomer Pipeline Expansion and New Liver and Genetic Disease Programs - TipRanks
ProQR updates RNA editing pipeline, targets biliary atresia - Investing.com
Pipeline expansion and cash runway into 2027 for ProQR (PRQR) - Stock Titan
ProQR picks rare liver disease for lead drug as more data nears - Stock Titan
ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst CallSlideshow (NASDAQ:PRQR) 2026-04-08 - Seeking Alpha
ProQR Therapeutics N.V. Establishes AI Advisory Board - marketscreener.com
ProQR in pact with Ginkgo as part of AI strategy (PRQR:NASDAQ) - Seeking Alpha
ProQR Partners with Ginkgo Bioworks, Launches AI Advisory Board to Drive Axiomer RNA Drug Discovery - TipRanks
ProQR announces partnership with Ginkgo Bioworks and formation of AI advisory board - marketscreener.com
ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board - The Manila Times
ProQR partners with Ginkgo on AI drug discovery platform - Investing.com
AI deal with Ginkgo boosts ProQR (NASDAQ: PRQR) Axiomer RNA editing plans - Stock Titan
PRQR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
PROQR THERAPEUTICS NV PB Ratio: 3.11 — Near Median - gurufocus.com
Analysts Set $6.80 Price Target for ProQR Therapeutics - National Today
ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
What analysts say about ProQR Therapeutics NV stockWeekly Trend Recap & Expert Verified Movement Alerts - baoquankhu1.vn
US Market Recap: Can ProQR Therapeutics NV benefit from deglobalization2026 Summary & Detailed Earnings Play Alerts - baoquankhu1.vn
Aug Reactions: Can ProQR Therapeutics NV weather a recessionMarket Growth Report & AI Forecasted Entry and Exit Points - baoquankhu1.vn
PRQR SEC FilingsProqr Therapeuti 10-K, 10-Q, 8-K Forms - Stock Titan
Retail Trends: Will ProQR Therapeutics NV stock recover after earningsIPO Watch & Safe Swing Trade Setup Alerts - baoquankhu1.vn
ProQR Sets April 8 Virtual Investor Event to Spotlight Axiomer RNA Editing Pipeline - The Globe and Mail
Price Action: Is ProQR Therapeutics NV attractive for institutional investors2026 Pullback Review & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Growing Optimism About ProQR Therapeutics (PRQR)’s RNA Editing Platform and Future Clinical Catalysts - Yahoo Finance
ProQR (PRQR) schedules April 8 virtual event on Axiomer RNA pipeline - Stock Titan
ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026 - GlobeNewswire
Evercore ISI Group Initiates Coverage of ProQR Therapeutics N.V. (PRQR) with Outperform Recommendation - MSN
Research Analysts Set Expectations for PRQR Q2 Earnings - Defense World
ProQR (NASDAQ: PRQR) director details substantial share and long-dated option holdings - Stock Titan
ProQR (PRQR) CSO details sizeable option grants and share stake - Stock Titan
Director Maier details ProQR (PRQR) share option grants and vesting - Stock Titan
ProQR (PRQR) director Alison Lawton details multiple option grants - Stock Titan
ProQR (PRQR) CFO discloses 1,000,000-share option position in Form 3 - Stock Titan
Finanzdaten der Proqr Therapeutics N V-Aktie (PRQR)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):